We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-9.09%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
-$3.15B
Cap. Flow
+$225M
Cap. Flow %
1.29%
Top 10 Hldgs %
85.01%
Holding
121
New
2
Increased
15
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
KOD icon
Kodiak Sciences
KOD
+$48.8M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
4
TSVT
2seventy bio
TSVT
+$20.9M
5
REPL icon
Replimune Group
REPL
+$19.2M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$20.1M
2
LEGN icon
Legend Biotech
LEGN
+$19M
3
OPT
Opthea Limited American Depositary Shares
OPT
+$3.19M
4
ALBO
Albireo Pharma Inc
ALBO
+$2.43M
5
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
26
Krystal Biotech
KRYS
$10.7B
$53.7M 0.31%
807,735
– –
INSM icon
27
Insmed
INSM
$22.6B
$50.7M 0.29%
2,156,001
– –
PACB icon
28
Pacific Biosciences
PACB
$432M
$49.5M 0.28%
5,444,963
– –
RYTM icon
29
Rhythm Pharmaceuticals
RYTM
$7.39B
$47.5M 0.27%
4,125,062
+261,823
+7% +$2.3M
HRTX icon
30
Heron Therapeutics
HRTX
$92.5M
$46.5M 0.27%
8,131,678
– –
TRDA icon
31
Entrada Therapeutics
TRDA
$241M
$44.2M 0.25%
4,704,419
– –
TIL icon
32
Instil Bio
TIL
$49.2M
$41.9M 0.24%
194,685
– –
ALKS icon
33
Alkermes
ALKS
$8.14B
$39.5M 0.23%
1,500,000
– –
KDNY
34
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$38.2M 0.22%
2,334,102
– –
VSTM icon
35
Verastem
VSTM
$518M
$38.1M 0.22%
2,249,075
+458,106
+26% +$7.89M
JBIO
36
Jade Biosciences
JBIO
$1.15B
$37.9M 0.22%
59,143
+6,806
+13% +$2.64M
IMTX icon
37
Immatics
IMTX
$1.18B
$35.3M 0.2%
4,423,731
– –
TSVT
38
DELISTED
2seventy bio
TSVT
$35.2M 0.2%
2,062,744
+1,229,508
+148% +$20.9M
NRIX icon
39
Nurix Therapeutics
NRIX
$2.45B
$34.4M 0.2%
2,454,082
– –
VERV
40
DELISTED
Verve Therapeutics
VERV
$32.3M 0.19%
1,416,530
– –
RARE icon
41
Ultragenyx Pharmaceutical
RARE
$2.51B
$32.3M 0.19%
444,444
– –
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$6.13B
$27.8M 0.16%
2,799,577
– –
REPL icon
43
Replimune Group
REPL
$441M
$27.4M 0.16%
1,611,703
+1,018,308
+172% +$19.2M
AXSM icon
44
Axsome Therapeutics
AXSM
$11.9B
$25.3M 0.15%
610,970
– –
DBVT
45
DBV Technologies
DBVT
$798M
$23.2M 0.13%
1,461,426
– –
DSGN icon
46
Design Therapeutics
DSGN
$743M
$23.2M 0.13%
1,436,636
– –
CCXI
47
DELISTED
ChemoCentryx, Inc.
CCXI
$23M 0.13%
916,862
-714,404
-44% -$20.1M
XENE icon
48
Xenon Pharmaceuticals
XENE
$6.19B
$23M 0.13%
751,639
– –
AFMD
49
DELISTED
Affimed
AFMD
$22.5M 0.13%
515,317
+250,000
+94% +$10.9M
ADAP
50
DELISTED
Adaptimmune Therapeutics
ADAP
$20.3M 0.12%
9,830,877
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Baker Bros. Advisors held 121 positions worth $17.4B, down 15% from $20.6B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Trading was light in Q1 2022: portfolio turnover was 4.1%. Baker Bros. Advisors opened 2 new positions and exited 3, leaving the 121-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2022 buy was Vera Therapeutics: 333,333 shares worth $7.83M.
  • Baker Bros. Advisors added most to Incyte in Q1 2022, an estimated $184M increase.
  • Baker Bros. Advisors's biggest Q1 2022 reduction was ChemoCentryx, Inc., cutting an estimated $20.1M.
  • Baker Bros. Advisors fully exited Albireo Pharma Inc in Q1 2022, selling an estimated $2.43M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $17.4B portfolio in Q1 2022.
  • Baker Bros. Advisors opened 2 new positions and closed 3 in Q1 2022.
  • Baker Bros. Advisors's portfolio value fell 15% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q1 2022, filed 16 May 2022.